EPAspire (eicosapentaenoic acid free fatty acid)
/ KD Biopharma, SLA Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
April 25, 2024
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
(clinicaltrials.gov)
- P3 | N=204 | Active, not recruiting | Sponsor: S.L.A. Pharma AG | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2024 ➔ Jul 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024
Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • APC
October 27, 2022
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
(clinicaltrials.gov)
- P3 | N=204 | Recruiting | Sponsor: S.L.A. Pharma AG | Trial primary completion date: Dec 2022 ➔ Dec 2023
Trial primary completion date • Genetic Disorders • APC
July 23, 2022
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
(clinicaltrials.gov)
- P3 | N=204 | Recruiting | Sponsor: S.L.A. Pharma AG | Trial primary completion date: Dec 2023 ➔ Dec 2022
Trial primary completion date • Genetic Disorders • APC
December 03, 2021
EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)
(clinicaltrials.gov)
- P3; N=284; Recruiting; Sponsor: S.L.A. Pharma AG; Not yet recruiting ➔ Recruiting; Trial completion date: Jul 2021 ➔ Dec 2021; Trial primary completion date: Jul 2021 ➔ Nov 2021
Clinical • Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL6
July 14, 2021
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
(clinicaltrials.gov)
- P3; N=204; Recruiting; Sponsor: S.L.A. Pharma AG; Trial completion date: Mar 2021 ➔ Jan 2024; Trial primary completion date: Mar 2021 ➔ Dec 2023
Clinical • Trial completion date • Trial primary completion date • Genetic Disorders • APC
January 16, 2019
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
(clinicaltrials.gov)
- P3; N=204; Recruiting; Sponsor: S.L.A. Pharma AG
Clinical • New P3 trial • Genetic Disorders • APC
November 02, 2020
EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)
(clinicaltrials.gov)
- P3; N=284; Not yet recruiting; Sponsor: S.L.A. Pharma AG; Trial completion date: Jul 2020 ➔ Jul 2021; Initiation date: Apr 2020 ➔ Nov 2020; Trial primary completion date: Jul 2020 ➔ Jul 2021
Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • IL6
May 02, 2020
EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)
(clinicaltrials.gov)
- P3; N=240; Not yet recruiting; Sponsor: S.L.A. Pharma AG; N=150 ➔ 240
Clinical • Enrollment change • Infectious Disease • Novel Coronavirus Disease • IL6
April 06, 2020
EPA-FFA to Treat Hospitalised Patients With SARS-CoV-2
(clinicaltrials.gov)
- P3; N=150; Not yet recruiting; Sponsor: S.L.A. Pharma AG
Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease
April 14, 2020
KD Pharma Group & SLA Pharma initiate clinical trial for Covid-19
(Businesswire)
- "The KD Pharma Group ('KD Pharma') and its partner, SLA Pharma ('SLA'), announced that its new drug candidate EPAspire™ is shortly entering clinical trials as a promising candidate to treat patients with symptoms of the novel coronavirus infection. The MHRA in the UK has approved the trial and late-stage discussions are ongoing with authorities in other European countries. Additionally, an application has been submitted to the FDA in the US. It is expected that the first patients in the trial will be enrolled shortly and additional hospital sites are being recruited for the trial."
European regulatory • FDA event • New trial • Infectious Disease • Novel Coronavirus Disease
1 to 10
Of
10
Go to page
1